ANN ARBOR—The pharmaceutical firm Esperion Therapeutics Inc. feported a rise in sales of its novel cholesterol-reducing drugs in the second quarter ended June 30 but still posted a loss as efforts to boost the drug’s sales continue. The company posted a loss of $43.7 million or $1.67 a share in the quarter, compared to net
ANN ARBOR—Esperion Therapeutics Inc. reported a loss of $85.4 million or $3.07 a share in the third quarter of 2020, vs. a loss of $68.4 million or $2.52 a share in the same quarter of 2019. Revenue was $3.8 million, including $3.3 million in product sales and $500,000 in partner reimbursement. Revenue a year earlier
ANN ARBOR—After years of development, Nexletol, the new cholesterol-reducer from Ann Arbor’s Esperion Therapeutics Inc., is now on the market and available in pharmacies in the United States. Nexletol uses a new mechanism of action to reduce low-density lipoprotein (LDL-C), the so-called bad cholesterol in the bloodstream, the cholesterol that can cause arterial blockages that
ANN ARBOR—Cholesterol-lowering drug developer Esperino Therapeutics Inc. has appointed Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. “On behalf of the Lipid Management team and our directors, I am very pleased to welcome Alan to the Esperion board. His extensive financial leadership experience will be extremely
ANN ARBOR—Esperion Therapeutics Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a “positive opinion” for both its bempedoic acid and its benpedoic acid-ezetimibe tablets to treat high cholesterol and other risky conditions involving lipids in the bloodstream. Company officials said the committee “found there were no
ANN ARBOR — Esperion Therapeutics Inc., the Ann Arbor-based pharmaceutical developer, announced positive results from the final Phase 3 test of its lead drug candidate, bempedoic acid. The company said a global, pivotal Phase 3 clinical study (Study 1002-047) showed that a dose of 180 milligrams per day of the drug showed additional lowering of
ANN ARBOR — Esperion Therapeutics Inc. announced positive top-line results from the third of five pivotal Phase 3 studies expected to be reported this year to evaluate the efficacy in lowering so-called bad cholesterol. The tests were done on Esperion's, lead drug candidate, bempedoic acid, at a dose of 180 milligrams, vs. placebo in high-risk patients
ANN ARBOR — Esperion Therapeutics Inc. Monday announced the start of a Phase 3 study to assess the safety and efficacy of a combination pill containing its cholesterol-fighter, bempedoic acid, with ezetimibe, a drug that decreases cholesterol absorption in the small intestine. Ezetimibe is used when other cholesterol-lowering medications, such as statins, are not tolerated
